Tarsus Pharmaceuticals' Xdemvy (lotilaner) has become the first FDA-approved therapy for Demodex blepharitis, a condition that affects up to 25 million people in the US and can lead to red itchy ...

He adds: "If your blepharitis is linked to Demodex mites, your doctor may also recommend daily cleansing of the eye area with warm water. "Warm compresses can also help to reduce swelling ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Eyelash dandruff, though often underestimated, has the potential to disrupt your eye health and overall well-being. Vigilance ...

The company's strategic moves appear to be setting the stage for sustained progress in the treatment of Demodex blepharitis. While analysts project continued sales growth, detailed financial ...

results of an ongoing Demodex blepharitis prevalence study expected in 2025 Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea ...

XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...